Literature DB >> 10049278

Use of an isogenic Escherichia coli panel to design tests for discrimination of beta-lactamase functional groups of Enterobacteriaceae.

A F Ehrhardt1, C C Sanders, E S Moland.   

Abstract

A study was designed to determine if an isogenic panel of Escherichia coli strains containing many different beta-lactamases could be used for the preliminary screening of a large number of beta-lactam agents to identify which might be most useful in the development of a definitive test for specific beta-lactamases found among the members of family Enterobacteriaceae. The susceptibilities of 46 strains, comprising the isogenic panel, to expanded-spectrum cephalosporins, cephamycins, and aztreonam were determined in the presence and absence of beta-lactamase inhibitors in broth microdilution tests. The results indicated that strains producing extended-spectrum beta-lactamases (ESBLs) could be distinguished from strains producing other Bush-Jacoby-Medeiros functional group 2 or group 1 beta-lactamases. For strains producing group 1 beta-lactamases, cefpodoxime and ceftazidime MICs were > or = 4 micrograms/ml and addition of clavulanate did not reduce the MICs more than fourfold. For strains producing group 2 enzymes other than ESBLs, cefpodoxime and ceftazidime MICs were < or = 2 micrograms/ml. With a single exception (ceftazidime for the strain producing SHV-3), among strains producing ESBLs, cefpodoxime and ceftazidime MICs were > or = 4 micrograms/ml and addition of clavulanate reduced the MICs by more than eightfold. Cephamycins could also be used to discriminate between strains producing group 1 beta-lactamases and ESBLs, since only the former required cefotetan concentrations as high as 8 micrograms/ml or cefoxitin concentrations of > 16 micrograms/ml for inhibition. Other cephalosporins provided some discrimination between the various beta-lactamase producers, although they were not as reliable as either cefpodoxime or ceftazidime. These results indicate the utility of an isogenic panel for identification of candidate drugs among many for further testing with clinical isolates of the family Enterobacteriaceae to determine the best agents for detection of specific beta-lactamases in this family.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10049278      PMCID: PMC89171     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Comparison of screening methods for detection of extended-spectrum beta-lactamases and their prevalence among blood isolates of Escherichia coli and Klebsiella spp. in a Belgian teaching hospital.

Authors:  E Vercauteren; P Descheemaeker; M Ieven; C C Sanders; H Goossens
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

Review 2.  Characterization of beta-lactamases.

Authors:  K Bush
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

3.  In vivo selection of a cephamycin-resistant, porin-deficient mutant of Klebsiella pneumoniae producing a TEM-3 beta-lactamase.

Authors:  B Pangon; C Bizet; A Buré; F Pichon; A Philippon; B Regnier; L Gutmann
Journal:  J Infect Dis       Date:  1989-05       Impact factor: 5.226

Review 4.  A functional classification scheme for beta-lactamases and its correlation with molecular structure.

Authors:  K Bush; G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

5.  Development of test panel of beta-lactamases expressed in a common Escherichia coli host background for evaluation of new beta-lactam antibiotics.

Authors:  P A Bradford; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

6.  Detection of Klebsiella pneumoniae and Escherichia coli strains producing extended-spectrum beta-lactamases.

Authors:  G P Katsanis; J Spargo; M J Ferraro; L Sutton; G A Jacoby
Journal:  J Clin Microbiol       Date:  1994-03       Impact factor: 5.948

7.  Nucleotide sequence of a plasmid-mediated cephalosporinase gene (blaLAT-1) found in Klebsiella pneumoniae.

Authors:  L S Tzouvelekis; E Tzelepi; A F Mentis
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

8.  TEM-28 from an Escherichia coli clinical isolate is a member of the His-164 family of TEM-1 extended-spectrum beta-lactamases.

Authors:  P A Bradford; N V Jacobus; N Bhachech; K Bush
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

9.  Expression of the AsbA1, OXA-12, and AsbM1 beta-lactamases in Aeromonas jandaei AER 14 is coordinated by a two-component regulon.

Authors:  L E Alksne; B A Rasmussen
Journal:  J Bacteriol       Date:  1997-03       Impact factor: 3.490

Review 10.  beta-Lactam resistance in gram-negative bacteria: global trends and clinical impact.

Authors:  C C Sanders; W E Sanders
Journal:  Clin Infect Dis       Date:  1992-11       Impact factor: 9.079

View more
  6 in total

1.  BetalasEN: microdilution panel for identifying beta-lactamases present in isolates of Enterobacteriaceae.

Authors:  Christine C Sanders; Anton F Ehrhardt; Ellen Smith Moland; Kenneth S Thomson; Barbara Zimmer; Darcie E Roe
Journal:  J Clin Microbiol       Date:  2002-01       Impact factor: 5.948

2.  Contribution of natural amino acid substitutions in SHV extended-spectrum beta-lactamases to resistance against various beta-lactams.

Authors:  C C Randegger; A Keller; M Irla; A Wada; H Hächler
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

3.  Phenotypic and molecular detection of CTX-M-beta-lactamases produced by Escherichia coli and Klebsiella spp.

Authors:  Johann D D Pitout; Ashfaque Hossain; Nancy D Hanson
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

4.  Detection of Pseudomonas aeruginosa producing metallo-beta-lactamases in a large centralized laboratory.

Authors:  Johann D D Pitout; Daniel B Gregson; Laurent Poirel; Jo-Ann McClure; Phillip Le; Deirdre L Church
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

5.  Clinically relevant Gram-negative resistance mechanisms have no effect on the efficacy of MC-1, a novel siderophore-conjugated monocarbam.

Authors:  Craig J McPherson; Lisa M Aschenbrenner; Brian M Lacey; Kelly C Fahnoe; Margaret M Lemmon; Steven M Finegan; Baswanth Tadakamalla; John P O'Donnell; John P Mueller; Andrew P Tomaras
Journal:  Antimicrob Agents Chemother       Date:  2012-10-01       Impact factor: 5.191

6.  Use of microdilution panels with and without beta-lactamase inhibitors as a phenotypic test for beta-lactamase production among Escherichia coli, Klebsiella spp., Enterobacter spp., Citrobacter freundii, and Serratia marcescens.

Authors:  K S Thomson; C C Sanders; E S Moland
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.